A consistent treatment of medium effects on hypernuclear pi-mesonic decay

por Ericson, M, Bando, H
Publicado 1990

INS International Symposium on Hypernuclear Physics

por Bando, H, Hashimoto, O, Ogawa, K
Publicado 1986

Reply: KRAS mutation in colorectal cancer metastases after adjuvant folfox for the primary

por Yoshino, T, Kawamoto, Y, Bando, H, Tsuchihara, K
Publicado 2012

Comparative analysis of interleukin 15 and interleukin 2 for induction of killer activity and of type 2 cytokine production by mononuclear cells from lung cancer patients.

por Takeuchi, E., Yanagawa, H., Suzuki, Y., Bando, H., Sone, S.
Publicado 1998

Introduction of the Kaifu telemedicine system for emergency medicine to ambulance services with improvement of the survival rates

por Obata, F, Tabata, R, Mori, K, Kageji, T, Tani, K, Bando, H
Publicado 2014

Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer

por Bando, H, Weich, H A, Brokelmann, M, Horiguchi, S, Funata, N, Ogawa, T, Toi, M
Publicado 2005

New support system using a mobile device for diagnostic image display and treatment of acute stroke in Japanese depopulated areas

por Kageji, T, Oka, H, Obata, F, Tani, K, Bando, H, Tabata, R, Kohno, M
Publicado 2014

Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer

por Toi, M, Bando, H, Horiguchi, S, Takada, M, Kataoka, A, Ueno, T, Saji, S, Muta, M, Funata, N, Ohno, S
Publicado 2004

Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer

por Kubota, Y., Kawazoe, A., Mishima, S., Nakamura, Y., Kotani, D., Kuboki, Y., Bando, H., Kojima, T., Doi, T., Yoshino, T., Kuwata, T., Shitara, K.
Publicado 2023

Differential isoform expression of SERCA and myosin heavy chain in hypopharyngeal muscles

por ELRABIE AHMED, MOHAMMED, BANDO, H., FUSE, S., MOSTAFA ABDELFATTAH, H., ELRABIE AHMED, MONA, ABDEL-KADER AHMED, M., TSUJIKAWA, T., HISA, Y.
Publicado 2019

KRAS mutations detected by the amplification refractory mutation system–Scorpion assays strongly correlate with therapeutic effect of cetuximab

por Bando, H, Yoshino, T, Tsuchihara, K, Ogasawara, N, Fuse, N, Kojima, T, Tahara, M, Kojima, M, Kaneko, K, Doi, T, Ochiai, A, Esumi, H, Ohtsu, A
Publicado 2011

Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for...

por Masuda, N., Toi, M., Yamamoto, N., Iwata, H., Kuroi, K., Bando, H., Ohtani, S., Takano, T., Inoue, K., Yanagita, Y., Kasai, H., Morita, S., Sakurai, T., Ohno, S.
Publicado 2018

KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer

por Kawamoto, Y, Tsuchihara, K, Yoshino, T, Ogasawara, N, Kojima, M, Takahashi, M, Ochiai, A, Bando, H, Fuse, N, Tahara, M, Doi, T, Esumi, H, Komatsu, Y, Ohtsu, A
Publicado 2012

Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil–epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory...

por Ohno, S., Chow, L. W. C., Sato, N., Masuda, N., Sasano, H., Takahashi, F., Bando, H., Iwata, H., Morimoto, T., Kamigaki, S., Nakayama, T., Nakamura, S., Kuroi, K., Aogi, K., Kashiwaba, M., Yamashita, H., Hisamatsu, K., Ito, Y., Yamamoto, Y., Ueno, T., Fakhrejahani, E., Yoshida, N., Toi, M.
Publicado 2013

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer

por Yoshino, T., Cervantes, A., Bando, H., Martinelli, E., Oki, E., Xu, R.-H., Mulansari, N.A., Govind Babu, K., Lee, M.A., Tan, C.K., Cornelio, G., Chong, D.Q., Chen, L.-T., Tanasanvimon, S., Prasongsook, N., Yeh, K.-H., Chua, C., Sacdalan, M.D., Sow (Jenson), W.J., Kim, S.T., Chacko, R.T., Syaiful, R.A., Zhang, S.Z., Curigliano, G., Mishima, S., Nakamura, Y., Ebi, H., Sunakawa, Y., Takahashi, M., Baba, E., Peters, S., Ishioka, C., Pentheroudakis, G.
Publicado 2023